171049-35-7

Basic information

• Product Name: N-BOC-4,4'-BIPIPERIDINE
• Synonyms: [4,4']BIPIPERIDINYL-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-(4'-PIPERID-1-YL)-1-TERT-BUTOXYCARBONYL PIPERIDINE;N-BOC-4,4'-BIPIPERIDINE;N-(tert-Butoxycarbonyl)-4,4''-bipiperidine;1-Boc- 4,4\'-bipiperidine;4-Piperidin-4-ylpiperidine, N-BOC protected;tert-Butyl 4,4'-bipiperidine-1-carboxylate;tert-Butyl 4,4'-bipiperidine-1-carboxylate, 4-(tert-Butoxycarbonyl)-4-piperidin-4-ylpiperidine
• CAS NO: 171049-35-7
• Molecular Formula: C₁₅H₂₈N₂O₂
• Molecular Weight: 268.4
• Product Categories: pharmacetical
• Mol File: 171049-35-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 363℃
• Flash Point: 173℃
• Appearance: /
• Density: 1.028
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.38±0.10(Predicted)
• CAS DataBase Reference: N-BOC-4,4'-BIPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-4,4'-BIPIPERIDINE(171049-35-7)
• EPA Substance Registry System: N-BOC-4,4'-BIPIPERIDINE(171049-35-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 171049-35-7(Hazardous Substances Data)

Usage

General Description

N-BOC-4,4'-Bipiperidine is a chemical compound commonly used in organic synthesis and pharmaceutical research. It is a member of the piperidine class of compounds and is characterized by a bicyclic structure containing two piperidine rings linked by a four-carbon chain. The compound is N-BOC protected, meaning that the nitrogen atom of the piperidine rings is protected by a tert-butoxycarbonyl group, which can be removed under mild conditions. N-BOC-4,4'-Bipiperidine has been studied for its potential use as a building block in the synthesis of various biologically active compounds and drug candidates. It is also used as a precursor in the synthesis of ligands for asymmetric catalysis and in the development of new chemical entities for pharmacological applications. Overall, N-BOC-4,4'-Bipiperidine plays an important role in the field of organic chemistry and drug discovery.

Upstream product

• 15336-72-8 4,4'-bipiperidine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 78619-84-8 4,4'-bipiperidine dihydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 383859-24-3 1-(2-methoxybenzyl)-4,4'-bipiperidine 
• 171049-14-2 lotrafiban 
• 723300-27-4 C₂₃H₃₄N₂O₄ 
• 868707-25-9 C₂₃H₃₅N₃O₆S 
• 1034822-86-0 tert-butyl 1'-(2-chloro-4-cyanophenyl)-4,4'-bipiperidine-1-carboxylate 
• 1034822-26-8 tert-butyl 1'-[4-(methylsulfonyl)phenyl]-4,4'-bipiperidine-1-carboxylate 
• 1034822-28-0 tert-butyl 1'-{4-[(trifluoromethyl)sulfonyl]phenyl}-4,4'-bipiperidine-1-carboxylate 
• 1159687-78-1 C₂₅H₄₀N₂O₂ 
• 1039743-27-5 1-[4-(methylsulfonyl)phenyl]-1'-pyridin-2-yl-4,4'-bipiperidine 
• 1039743-19-5 1-[4-(methylsulfonyl)phenyl]-1'-pyrazin-2-yl-4,4'-bipiperidine 
• 1039743-18-4 1-[4-(methylsulfonyl)phenyl]-1'-pyrimidin-2-yl-4,4'-bipiperidine 
• 1310553-07-1 C₂₂H₃₄N₂O₂ 

Relevant articles and documents

Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's Disease

Herein, we describe the development of a functionally selective liver X receptor β (LXRβ) agonist series optimized for Emax selectivity, solubility, and physical properties to allow efficacy and safety studies in vivo. Compound 9 showed central pharmacodynamic effects in rodent models, evidenced by statistically significant increases in apolipoprotein E (apoE) and ATP-binding cassette transporter levels in the brain, along with a greatly improved peripheral lipid safety profile when compared to those of full dual agonists. These findings were replicated by subchronic dosing studies in non-human primates, where cerebrospinal fluid levels of apoE and amyloid-β peptides were increased concomitantly with an improved peripheral lipid profile relative to that of nonselective compounds. These results suggest that optimization of LXR agonists for Emax selectivity may have the potential to circumvent the adverse lipid-related effects of hepatic LXR activity.

[35S]GTPγS binding studies of amphiphilic drugs-activated Gi proteins: A caveat

This paper documents a serious problem met during the testing of Gi protein-activating properties of a new series of synthetic compounds by measuring the induced binding of [35S]GTPγS to different subtypes of Gi protein. The problem arose from the strong affinity between [35S]GTPγS and the tested compounds, that are characterized by several (2-4) positive charges and high lipophilicity. Apparently, such affinity yields insoluble, labelled complexes that, also in the absence of Gi protein, are retained on the filters and give rise to false positive results.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.